{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:55:43Z","timestamp":1762325743769,"version":"3.41.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"DOI":"10.13039\/501100006193","name":"College of Graduate Studies, Kuwait University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006193","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Topiramate (TPM) is used for the treatment of various epileptic seizures and the prevention of migraine. This study aimed to develop a population pharmacokinetic model and identify covariates that influence TPM behavior in patients with epilepsy in Kuwait.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data were collected retrospectively from 108 patients (2 years old and above) with epilepsy who were treated with oral TPM and 174 TPM blood samples from 3 hospitals in Kuwait from 2009 to 2016. Data were randomly divided into 2 groups for model development and validation. The population pharmacokinetic model was built using the nonparametric modeling algorithm (Pmetrics). The model was evaluated internally through the visual predictive check method and externally using a new data set.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A 1-compartment model with first-order elimination fitted the data well. Covariates showing a significant effect on the elimination rate constant were renal function and coadministration of carbamazepine (CBZ). The mean estimated clearance was 2.11 L\/h; this was 50% higher for patients coadministered with CBZ. Age and sex were essential covariates for the volume of distribution (V). The visual predictive check of the final model could predict the measured concentrations. External validation further confirmed the favorable predictive performance of the model with low bias and imprecision for predicting the concentration in a particular population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>TPM elimination was increased with CBZ coadministration and was affected by renal function. Meanwhile, age and sex were the main predictors for V. The predictive performance of the final model proved to be valid internally and externally.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001143","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T04:00:51Z","timestamp":1696564851000},"page":"797-804","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetics of Topiramate in Patients with Epilepsy Using Nonparametric Modeling"],"prefix":"10.1097","volume":"45","author":[{"given":"Mandy","family":"Elewa","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, College of Pharmacy, Kuwait University, Kuwait City, Kuwait;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-1483","authenticated-orcid":false,"given":"Sarah S.","family":"Alghanem","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Kuwait University, Kuwait City, Kuwait;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasem","family":"Al-Hashel","sequence":"additional","affiliation":[{"name":"Neurology Department, Ibn-Sina Hospital, Ministry of Health, Kuwait City, Kuwait;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Thussu","sequence":"additional","affiliation":[{"name":"Neurology Department, Al-Amiri Hospital, Ministry of Health, Kuwait City, Kuwait; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef","family":"Al-Lanqawi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Al-Amiri Hospital, Ministry of Health, Kuwait City, Kuwait."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Matar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, College of Pharmacy, Kuwait University, Kuwait City, Kuwait;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00023210-200115050-00001","article-title":"The new generation of GABA enhancers. Potential in the treatment of epilepsy","volume":"15","author":"Czuczwar","year":"2001","journal-title":"CNS Drugs"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1527-3458.2008.00041.x","article-title":"Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate","volume":"14","author":"Shank","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"R3-20250603","first-page":"105","article-title":"The effect of food on the bioavailability of topiramate from 100-and 400-mg tablets in healthy male subjects","volume":"33","author":"Doose","year":"1992","journal-title":"Epilepsia"},{"issue":"suppl 1","key":"R4-20250603","first-page":"S18","article-title":"Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs","volume":"38","author":"Johannessen","year":"1997","journal-title":"Epilepsia"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200645040-00002","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age","volume":"45","author":"Perucca","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.eplepsyres.2010.12.004","article-title":"Topiramate pharmacokinetics in infants and young children: contribution of population analysis","volume":"93","author":"Bouillon-Pichault","year":"2011","journal-title":"Epilepsy Res"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1528-1157.1996.tb06028.x","article-title":"Drug interaction profile of topiramate","volume":"37","author":"Bourgeois","year":"1996","journal-title":"Epilepsia"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","article-title":"Pharmacokinetic interactions of topiramate","volume":"43","author":"Bialer","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.seizure.2005.11.003","article-title":"Clinical experience with topiramate dosing and serum levels in patients with epilepsy","volume":"15","author":"Zanotta","year":"2006","journal-title":"Seizure"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1177\/088307380502000101","article-title":"Treatment of pediatric epilepsy: expert opinion","volume":"20","author":"Wheless","year":"2005","journal-title":"J Child Neurol"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00007691-200206000-00002","article-title":"Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs","volume":"24","author":"Contin","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1248\/bpb.33.1176","article-title":"A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy","volume":"33","author":"Vovk","year":"2010","journal-title":"Biol Pharm Bull"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejps.2013.07.008","article-title":"Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling","volume":"50","author":"Jovanovi\u0107","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2016.02.002","article-title":"Factors influencing topiramate clearance in adult patients with epilepsy: a population pharmacokinetic analysis","volume":"37","author":"Bae","year":"2016","journal-title":"Seizure"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/FTD.0000000000000383","article-title":"Population pharmacokinetics of topiramate in Japanese pediatric and adult patients with epilepsy using routinely monitored data","volume":"39","author":"Takeuchi","year":"2017","journal-title":"Ther Drug Monit"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00003088-200645040-00003","article-title":"Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies","volume":"45","author":"Bustad","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00007691-200006000-00019","article-title":"Population pharmacokinetics\/pharmaco-dynamics modeling: parametric and nonparametric methods","volume":"22","author":"Jelliffe","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cca.2010.02.003","article-title":"Therapeutic drug monitoring of topiramate by liquid chromatography-tandem mass spectrometry","volume":"411","author":"Matar","year":"2010","journal-title":"Clinica Chim Acta"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1017\/S1368980011003685","article-title":"Secular trends and risk factors of overweight and obesity among Kuwaiti adults: national Nutrition Surveillance System data from 1998 to 2009","volume":"15","author":"Ahmed","year":"2012","journal-title":"Public Health Nutr"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/sj.ejcn.1601961","article-title":"Body mass index, overweight and obesity among Kuwaiti intermediate school adolescents aged 10\u201314 years","volume":"58","author":"Al-Isa","year":"2004","journal-title":"Eur J Clin Nutr"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1466424006061176","article-title":"Body mass index of Kuwaiti children aged 3\u20139 years: reference percentiles and curves","volume":"126","author":"Al-Isa","year":"2006","journal-title":"J R Soc Promot Health"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2307\/1402499","article-title":"Systematic sampling: a critical review","volume":"50","author":"Iachan","year":"1982","journal-title":"Int Stat Rev"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R26-20250603","first-page":"662","article-title":"Plasma pharmacokinetics of topiramate: a new anticonvulsant in humans","volume":"29","author":"Easterling","year":"1988","journal-title":"Epilepsia"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"issue":"suppl 1","key":"R32-20250603","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003088-198900171-00005","article-title":"Clinical pharmacokinetics in infants and children. A reappraisal","volume":"17","author":"Kearns","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jppr.1787","article-title":"Significant predictors for topiramate pharmacokinetics: a systematic review of population pharmacokinetic studies","volume":"52","author":"Tippayachai","year":"2022","journal-title":"J Pharm Pract Res"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1528-1167.2005.06805.x","article-title":"A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy","volume":"46","author":"Mimrod","year":"2005","journal-title":"Epilepsia"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1528-1157.1997.tb01124.x","article-title":"Comparison of the steady\u2010state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy","volume":"38","author":"Rosenfeld","year":"1997","journal-title":"Epilepsia"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R37-20250603","first-page":"S397","article-title":"The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF)","volume":"10","author":"Gisclon","year":"1993","journal-title":"Pharm Res"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1528-1167.2010.02598.x","article-title":"Pharmacokinetic\u2013pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to < 10 years of age","volume":"51","author":"Girgis","year":"2010","journal-title":"Epilepsia"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003088-200544040-00005","article-title":"Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data","volume":"44","author":"Battino","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/00007691-200312000-00008","article-title":"Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response","volume":"25","author":"Ferrari","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00007691-200406000-00005","article-title":"Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications","volume":"26","author":"Ad\u00edn","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pediatrneurol.2004.04.005","article-title":"Age and antiepileptic drugs influence topiramate plasma levels in children","volume":"31","author":"Dahlin","year":"2004","journal-title":"Pediatr Neurol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:12:51Z","timestamp":1748970771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001143","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"2023-03-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}